Payment overview · 2025
General Payments
$1,733.37
87 reported records · 25 companies
Healthcare provider profile · identity verified
Riley Mark Hill, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BROKEN ARROW, OK · NPI 1508865361
Verified facts
What the public records show
CMS Open Payments records show Riley Mark Hill, MD received $1,733.37 in general payments during 2025 across 87 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $264.32 | 15.2% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $190.28 | 11.0% | 15 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $179.94 | 10.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $147.06 | 8.5% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $120.55 | 7.0% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.73 | 5.6% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $67.53 | 3.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $67.04 | 3.9% | 3 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $65.38 | 3.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $60.08 | 3.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.84 | 2.9% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $49.11 | 2.8% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $45.91 | 2.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.25 | 2.6% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $40.76 | 2.4% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $38.37 | 2.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $33.34 | 1.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.59 | 1.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.14 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.26 | 1.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.89 | 1.1% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.49 | 1.1% | 1 | 2025 |
| Hikma Pharmaceuticals USA | Unresolved — no canonical attribution shown | $16.97 | 1.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.22 | 0.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $14.32 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,690.87 | 86 |
| Education | $42.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $240.91 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $183.53 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $96.76 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $83.75 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.02 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.91 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $73.06 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.38 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.38 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $67.04 | 3 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $65.38 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $60.08 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $59.89 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.45 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $49.11 | 2 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $45.91 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $45.25 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $40.76 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $38.37 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.87 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $34.20 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $33.34 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.59 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $32.14 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.97 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.97 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.85 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.89 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $18.49 | 1 | 2025 |
Source payment records
|
|||||
| Ryaltris Normalized: ryaltris |
Drug | Hikma Pharmaceuticals USA | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 190 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 61 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 165 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 108 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
139 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 44 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
127 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
165 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
108 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 795 | 225 |
| Levothyroxine Sodium | Levothyroxine Sodium | 676 | 180 |
| Losartan Potassium | Losartan Potassium | 620 | 182 |
| Amlodipine Besylate | Amlodipine Besylate | 583 | 176 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 538 | 169 |
| Omeprazole | Omeprazole | 448 | 133 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 432 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 410 | 121 |
| Lisinopril | Lisinopril | 383 | 109 |
| Lorazepam | Lorazepam | 361 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 319 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 302 | 99 |
| Furosemide | Furosemide | 299 | 89 |
| Potassium Chloride | Potassium Chloride | 290 | 88 |
| Metformin Hcl | Metformin Hcl | 282 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 81 |
| Meloxicam | Meloxicam | 253 | 77 |
| Tramadol Hcl | Tramadol Hcl | 252 | 64 |
| Gabapentin | Gabapentin | 240 | 72 |
| Simvastatin | Simvastatin | 232 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 227 | 64 |
| Alprazolam | Alprazolam | 220 | 43 |
| Trazodone Hcl | Trazodone Hcl | 217 | 68 |
| Montelukast Sodium | Montelukast Sodium | 216 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 62 |
| Eliquis | Apixaban | 190 | 47 |
| Carvedilol | Carvedilol | 176 | 59 |
| Fluoxetine Hcl | Fluoxetine Hcl | 173 | 42 |
| Jardiance | Empagliflozin | 165 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 164 | 32 |
| Estradiol | Estradiol | 160 | 51 |
| Famotidine | Famotidine | 154 | 53 |
| Allopurinol | Allopurinol | 150 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 42 |
| Atenolol | Atenolol | 143 | 40 |
| Synthroid | Levothyroxine Sodium | 139 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 137 | 36 |
| Xarelto | Rivaroxaban | 127 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 125 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 121 | 50 |
| Temazepam | Temazepam | 121 | 18 |
| Warfarin Sodium | Warfarin Sodium | 121 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 47 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 30 |
| Ozempic | Semaglutide | 108 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 38 |
| Alendronate Sodium | Alendronate Sodium | 101 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 31 |
| Sertraline Hcl | Sertraline Hcl | 90 | 30 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 85 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 77 | 16 |
| Bupropion Xl | Bupropion Hcl | 76 | 25 |
| Ezetimibe | Ezetimibe | 76 | 21 |
| Januvia | Sitagliptin Phosphate | 73 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 71 | 21 |
| Ondansetron Odt | Ondansetron | 70 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 21 |
| Telmisartan | Telmisartan | 68 | 18 |
| Mounjaro | Tirzepatide | 66 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 64 | 16 |
| Donepezil Hcl | Donepezil Hcl | 62 | 18 |
| Prednisone | Prednisone | 62 | 37 |
| Farxiga | Dapagliflozin Propanediol | 61 | 16 |
| Finasteride | Finasteride | 61 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 20 |
| Methylprednisolone | Methylprednisolone | 60 | 55 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 56 | 18 |
| Buspirone Hcl | Buspirone Hcl | 56 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 18 |
| Pregabalin | Pregabalin | 53 | 13 |
| Aripiprazole | Aripiprazole | 52 | 13 |
| Celecoxib | Celecoxib | 52 | 17 |
| Metformin Hcl Er | Metformin Hcl | 52 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 11 |
| Propranolol Hcl | Propranolol Hcl | 52 | 12 |
| Mirtazapine | Mirtazapine | 51 | 11 |
| Novolog Flexpen | Insulin Aspart | 51 | 16 |
| Cephalexin | Cephalexin | 50 | 41 |
| Clonazepam | Clonazepam | 50 | 11 |
| Lovastatin | Lovastatin | 49 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 48 | 13 |
| Clonidine Hcl | Clonidine Hcl | 47 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 47 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 46 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | 12 |
| Ibuprofen | Ibuprofen | 45 | 12 |
| Spironolactone | Spironolactone | 45 | 14 |
| Trulicity | Dulaglutide | 44 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 33 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | 13 |
| Topiramate | Topiramate | 42 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 28 |
| Premarin | Estrogens, Conjugated | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 39 | suppressed |
| Diazepam | Diazepam | 39 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 29 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | suppressed |
| Levetiracetam | Levetiracetam | 37 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 13 |
| Azithromycin | Azithromycin | 34 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 34 | suppressed |
| Irbesartan | Irbesartan | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | 11 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Digoxin | Digoxin | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 28 | 17 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 16 |
| Baclofen | Baclofen | 26 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Kerendia | Finerenone | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 16 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 20 |
| Valsartan | Valsartan | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 19 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 13 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,733.37 · 87 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AFREZZA, AIRSUPRA, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, HORIZANT, JARDIANCE, KISUNLA, Kerendia, LEQVIO, LINZESS, LOREEV XR, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Ryaltris, Rybelsus, SPRAVATO, Symbravo, UBRELVY, VRAYLAR, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND, ZORYVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error